Antibiotic Granted FDA Approval for Expanded Indication to Include Certain Pneumonia
June 5th 2020The combination of imipenem-cilastatin and relebactam was previously approved by the FDA to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.
Read More